Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Operating Expenses (2016 - 2025)

Corcept Therapeutics' Operating Expenses history spans 10 years, with the latest figure at $197.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 26.18% year-over-year to $197.6 million; the TTM value through Dec 2025 reached $716.6 million, up 33.18%, while the annual FY2025 figure was $716.6 million, 33.18% up from the prior year.
  • Operating Expenses for Q4 2025 was $197.6 million at Corcept Therapeutics, roughly flat from $197.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $197.6 million in Q4 2025 and bottomed at $59.6 million in Q2 2021.
  • The 5-year median for Operating Expenses is $91.6 million (2023), against an average of $108.0 million.
  • The largest annual shift saw Operating Expenses decreased 2.77% in 2021 before it soared 50.99% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $62.2 million in 2021, then rose by 29.6% to $80.6 million in 2022, then grew by 28.77% to $103.7 million in 2023, then skyrocketed by 50.99% to $156.6 million in 2024, then increased by 26.18% to $197.6 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Operating Expenses are $197.6 million (Q4 2025), $197.4 million (Q3 2025), and $167.8 million (Q2 2025).